Natalie Shlafman brings over 20 years of marketing, commercialization and leadership experience. Prior to joining AEGEA, Natalie had been a consultant who worked with a diverse set of medical technology companies. She served as an interim marketing leader and advisor and drove market assessment and research, marketing strategy and execution, marketing communications and product launches. Before consulting, Natalie was the Vice President of Marketing at CardioDx, a cardiovascular genomic diagnostics company. During her tenure, she built out and directed the company’s marketing capabilities and drove all commercially-related aspects of developing, launching and driving adoption for the company’s flagship product. Prior to CardioDX, Natalie was in the Vascular Intervention Division of Guidant Corporation where she worked in market development within the New Ventures unit and in product marketing within the Angioplasty Systems group. Natalie started her career in the high-tech industry and held product marketing roles at LogicTier and at SGI. Natalie received her M.B.A. from Kellogg School of Management at Northwestern University and her B.A in psychology with a business specialization from UCLA.
Important Safety Information:
The Mara Water Vapor Ablation System is indicated to ablate the endometrial lining of the uterus in premenopausal women with menorrhagia due to benign causes for whom childbearing is complete. Pregnancy following the Mara procedure can be dangerous. The Mara procedure is not for those who have or suspect uterine cancer; have an active genital, urinary or pelvic infection; or an IUD. As with all surgical procedures, there are risks and considerations associated with the use of the Mara Water Vapor Ablation System. Please refer to the device labeling for a detailed discussion of the device’s intended use, relevant warnings, precautions, side effects, and contraindications.